ROCHESTER MEDICAL CORPORATION·4

Mar 4, 4:40 PM ET

SHOLTIS MARTYN R 4

4 · ROCHESTER MEDICAL CORPORATION · Filed Mar 4, 2013

Insider Transaction Report

Form 4
Period: 2013-02-28
SHOLTIS MARTYN R
Corporate Vice President
Transactions
  • Sale

    Common Stock

    2013-02-28$14.80/sh1,500$22,20340,000 total
  • Sale

    Common Stock

    2013-03-01$14.75/sh15,000$221,25040,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-03-0110,5000 total
    Exercise: $4.63From: 2005-01-02Exp: 2014-01-02Common Stock (10,500 underlying)
  • Exercise/Conversion

    Common Stock

    2013-03-01$4.70/sh+4,500$21,15055,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-02-281,50010,500 total
    Exercise: $4.63From: 2005-01-02Exp: 2014-01-02Common Stock (12,000 underlying)
  • Exercise/Conversion

    Common Stock

    2013-03-01$4.63/sh+10,500$48,56350,500 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2013-03-014,50025,500 total
    Exercise: $4.70From: 2006-01-01Exp: 2015-01-01Common Stock (30,000 underlying)
  • Exercise/Conversion

    Common Stock

    2013-02-28$4.63/sh+1,500$6,93841,500 total
Holdings
  • Stock Option (Right to Buy)

    Exercise: $11.27From: 2010-02-03Exp: 2019-02-03Common Stock (20,000 underlying)
    20,000
  • Stock Option (Right to Buy)

    Exercise: $12.30From: 2007-11-21Exp: 2016-11-21Common Stock (20,000 underlying)
    20,000
  • Stock Option (Right to Buy)

    Exercise: $5.70From: 2007-01-26Exp: 2016-01-26Common Stock (20,000 underlying)
    20,000
  • Stock Option (Right to Buy)

    Exercise: $11.23From: 2009-02-06Exp: 2018-02-06Common Stock (20,000 underlying)
    20,000
  • Stock Option (Right to Buy)

    Exercise: $12.27From: 2011-01-28Exp: 2020-01-28Common Stock (20,000 underlying)
    20,000
  • Stock Option (Right to Buy)

    Exercise: $10.72From: 2012-01-27Exp: 2021-01-27Common Stock (20,000 underlying)
    20,000
Footnotes (3)
  • [F1]Includes restricted stock award shares.
  • [F2]The price in Column 4 is a weighted average. The prices actually received ranged from $14.79 to $14.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Vest as to 25% annual cumulative installments beginning one year from date of grant, beginning the date shown.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION